Journal Mobile Options
Table of Contents
Vol. 34, No. 2, 1998
Issue release date: August 1998
Section title: Clinical Paper
Eur Urol 1998;34:107–110
(DOI:10.1159/000019693)

Bropirimine, an Orally Active Anticancer Agent for Superficial Bladder Cancer

Akaza H.a · Kotake T.b · Machida T.c
a Department of Urology, Institute of Clinical Medicine, University of Tsukuba; b Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; c School of Medicine, Jikei University, Tokyo, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 33.00
Account: USD 23.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of Clinical Paper

Published online: 8/7/1998
Issue release date: August 1998

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)

For additional information: http://www.karger.com/EUR

Abstract

Objective: To investigate efficacy and safety of bropirimine, a new orally active interferon inducer, in patients with superficial bladder cancer. Methods: Twenty patients with histologically confirmed recurrent superficial transitional cell carcinoma (Ta or T1) were studied. At least one marker lesion remained in all patients after transurethral resection. Bropirimine (750 mg) was given orally three times at 2-hour intervals (daily dose 2,250 mg) on 3 consecutive days weekly for 12 weeks. Results: Of the 17 evaluable patients, 1 did not complete the treatment protocol. There were 5 responders, including 2 with a complete response (complete disappearance of the marker tumor) and 3 with a partial response (>50% reduction of the marker tumor). The objective response rate was 31.3% (5/16; 95% confidence interval 11.0–58.7%) for the 16 patients completing treatment and 29.4% (5/17; 95% confidence interval 10.3–56.0%) for the 17 evaluable patients. Adverse reactions occurred in 70.6% of the evaluable patients. Flu-like symptoms were most common, including malaise (23.5%), headache (23.5), and fever (11.8%), followed by gastrointestinal symptoms including less of appetite (23.5%). All of these reactions were tolerable. Conclusions: Bropirimine may be useful for the prophylaxis of recurrence following transurethral resection of superficial bladder cancer because it shows efficacy against marker tumors and has a good safety profile and oral activity.


  

Article Information

Number of Print Pages : 4
Number of Figures : 0, Number of Tables : 2, Number of References : 18

  

Publication Details

European Urology
Official Organ of the European Association of Urology

Vol. 34, No. 2, Year 1998 (Cover Date: August 1998)

Journal Editor: C.C. Schulman, Brussels
ISSN: 0302–2838 (print), 1421–993X (Online)

For additional information: http://www.karger.ch/journals/eur


Article / Publication Details

First-Page Preview
Abstract of Clinical Paper

Published online: 8/7/1998
Issue release date: August 1998

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)

For additional information: http://www.karger.com/EUR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.